Plain-English Summary
FDA compounded ketamine warning in Patients and clinicians considering compounded ketamine products for psychiatric disorders. Ketamine is not FDA approved for treatment of any psychiatric disorder.
VV Study Evidence Matrix v1.0
VV Evidence Utility Score
A bounded score for how useful this study is in public explanation, based on evidence tier, design, applicability, endpoint relevance, limitations, safety signals, and publication/source strength.
76/100
Useful Public Evidence
- Evidence tier
- 92/100, weight 18%
- Design strength
- 92/100, weight 18%
- Applicability
- 75/100, weight 16%
- Endpoint relevance
- 58/100, weight 16%
- Limitations transparency
- 50/100, weight 12%
- Safety signal usefulness
- 57/100, weight 10%
- Publication/source strength
- 94/100, weight 10%
Useful for context, but limited by limitations transparency, safety signal usefulness, endpoint relevance.
How the study framework works ->Key Findings
- Ketamine is not FDA approved for treatment of any psychiatric disorder.
- Compounded ketamine products are not FDA approved for safety, effectiveness, or quality.
- Known concerns include sedation, dissociation, abuse and misuse, psychiatric events, increased blood pressure, respiratory depression, and urinary/bladder symptoms.
Limitations
- Regulatory safety page; it does not evaluate every supervised ketamine-care model.
Why It Matters
Regulatory safety concerns for compounded ketamine products, especially without appropriate monitoring.
Viral Vitalism Verdict
Useful evidence, bounded by design: Regulatory safety page; it does not evaluate every supervised ketamine-care model.
Sources
- FDA warns about compounded ketamine products for psychiatric disorders - U.S. Food and Drug Administration
Signal cards
Used in signals
Signal coverage connected to this study through explicit study links, canonical source refs, or evidence visualizations.
Does Cannabis Shrink Your Brain?
A viral claim turns cannabis brain research into a one-line shrinkage scare. The evidence is messier: blood flow, activation, volume, cognition, age, dose, and heavy-use patterns are not interchangeable.
VV Signal Score
58
Early or context-dependent
- Sources
- 10
- Studies
- 7
- Claims
- 7
Claim ledger
Relevant claims
Claim ledger records connected through this study's ID, topic tags, or source IDs.
ketamine: Ketamine should not be framed as a casual relaxation
Ketamine should not be framed as a casual relaxation substitute for cannabis; FDA warns about meaningful safety and monitoring concerns for compounded ketamine products.
cannabis: The broad claim that cannabis shrinks your brain overstates
The broad claim that cannabis shrinks your brain overstates a mixed evidence base and swaps endpoints such as perfusion, activation, volume, and cognition.
tanning: Tanning beds are not a safer substitute for perineum
Tanning beds are not a safer substitute for perineum sunning or sunlight; UV-emitting tanning devices increase dermatologic risk and are classified as carcinogenic exposures.
tanning: A tan provides only minimal protection and should not
A tan provides only minimal protection and should not be treated as meaningful SPF or as a safe skin-cancer prevention strategy.
raw milk: Raw milk is not safer than pasteurized milk because
Raw milk is not safer than pasteurized milk because pasteurization is designed to reduce disease-causing germs while preserving milk’s nutritional role.
raw milk: Children are a higher-risk group for serious illness from
Children are a higher-risk group for serious illness from raw milk pathogens, making child-focused raw-milk recommendations materially different from adult food-choice arguments.